^
Association details:
| Biomarker: | MBD4 deletion |
|---|---|
| Cancer: | Uveal Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients
Published date:
07/18/2022
Excerpt:
Median PFS was 4.0 months in MBD4 wild-type and 22.3 months in MBD4m patients (HR = 0.22; p = 0.01). Median OS in MBD4def patients was unreached as compared to 16.6 months in MBD4pro (HR = 0.11; 95% CI: 0.02-0.86; log-rank p-test = 0.04; Fig. 2e)....In mUM patients, MBD4 mutation is highly predictive for the response, PFS, and overall survival benefit to ICI.
DOI:
10.1016/j.ejca.2022.06.033
